May 22nd, 2007, by David Pascoe | tetracyclines
Collagenex has announced that their ongoing trials to find the best dosage for Incyclinide have discovered that 40mg can cause photo-toxicity.
Collagenex is conducting parallel Phase II trials for Incyclinide for both acne and rosacea.
As detailed in a recent news item, incyclinide targets conditions other than rosacea, Incyclinide differs from a non-antibiotic tetracycline in that it is also chemically modified. Thus we might expect that …
April 24th, 2007, by David Pascoe | tetracyclines
There has been a lot of publicity lately about Oracea, which is a low dosage, sustained release 40mg form of doxycyline. Oracea was born out of the expiration of the patent on periostat – a twice a day 20mg dose of doxycycline originally targetted at gum disease. Another new low dose antiobiotic is Solodyn (45mg, 90mg and 135mg of extended release minocycline HCL, dose …
April 20th, 2007, by David Pascoe | tetracyclines
This article, just published is adding to body of research of the anti-inflammatory actions of the tetracycline family. Recent related studies have been undertaken during the development of low dose doxycycline, for eg. oracea. So far this abstract isn’t teasing us with anything new. A similarly titled paper from 2006, Tetracyclines: their non-antibiotic properties also addressed this topic. Anti-Inflammatory Activity …
November 16th, 2006, by David Pascoe | rosacea cause, tetracyclines
In a recently published paper (previously mentioned only via the Abstract – Tetracyclines: their non-antibiotic properties ) we can read some more about how the regular, non-antibiotic (low dose) and chemically modified tetracycline analogues target rosacea.
Tetracyclines: nonantibiotic properties and their clinical implications., Journal American Academy of Dermatology, 2006 Feb;54(2):258-65., Allen N. Sapadin MD, and Raul Fleischmajer MD.
Mechanisms of action of tetracycline …
November 14th, 2006, by David Pascoe | tetracyclines
Rosacea News first wrote about Col-3 in August 2005 – COL-3 new tetracycline derivative being studied. We’ve also mentioned that COL-3 was renamed to Incyclinide – Incyclinide (CollaGenex) gets NIH Funding and Incyclinide phase 2 for acne.
In a recently published paper (previously mentioned only via the Abstract – Tetracyclines: their non-antibiotic properties ) we can read some more information about Incyclinide …
